Aberrant regulation of the pRB/E2F1 pathway has been invariably linked to inappropriate proliferation and/apoptosis in human cancers. Therefore, understanding the intricacies of the signaling pathway and identification of novel E2F1 targets involved in apoptosis could pave way for new therapeutic manipulation. Here, we identified CTSL2 (cathepsin L2/cathepsin V) as a novel E2F1 target that participates in E2F1-dependent apoptosis. We showed that E2F1 directly binds to CTSL2 promoter and that CTSL2 is regulated by both exogenous and endogenous E2F1. RNAi-mediated depletion of CTSL2 effectively abrogated ectopic E2F1-induced apoptosis, coupled with reduced lysosomal membrane permeabilization (LMP) and mitochondrial membrane depolarization. CTSL2 knockdown also inhibited apoptosis mediated by the endogenous E2F1 activated by DNA damage. Furthermore, we showed that CTSL2 depletion in cancer cells resulted in inhibition of histone deacetylase inhibitor (HDACi)-induced apoptosis, and conversely ectopic overexpression of CTSL2-sensitized cancer cells to HDACi. This study uncovered a novel E2F1 target implicated in LMP and apoptosis activation, as well as in the modulation of HDACi and chemotherapeutic drugs response.
INTRODUCTION
E2F transcription factor family members have diverse roles in cellular physiology and homeostasis. 1, 2 Among them, E2F1 (and perhaps E2F3) possesses a unique ability to induce apoptosis, 3 which has been regarded as a fail-safe mechanism to protect cells from aberrant oncogenic activation of Rb/E2F1 pathway. 4, 5 Therefore, cancer cells with aberrant activity of E2F1 may preferentially undergo apoptosis in certain context or upon drug treatment, thus providing a therapeutic window for tumor eradication. Although it is not exactly clear how E2F1 possesses biphasic properties on cellular proliferation and death, the critical concentration of E2F1 has been proposed to be a critical regulating point, with high E2F1 level preferentially driving cellular proliferation, while an excessive E2F1 level tips the cellular balance to death. 6, 7 It is well known that E2F1-induced cell death relies on its ability to transactivate various target genes of which protein products are prominent cell death mediators, 5, 8 in both p53-dependent and p53-independent manner. For example, E2F1-mediated transactivation of p19ARF would result in p53 stabilization and eventual execution of p53-mediated apoptosis, 9 whereas the activation of various cell death mediators, such as p73, 10, 11 APAF1, 12 ASK1, 13 caspases 14 and pro-apoptotic Bcl-2 family members, 15, 16 may lead to apoptosis in the absence of p53. However, relatively little is known about E2F1 apoptotic targets that are functionally important for the therapeutic response of anticancer drugs.
Here, through a large-scale gene expression analysis using an E2F1-confined system, we identified CTSL2 gene, encoding cathepsin like 2 (cathepsin L2/cathepsin V), as a novel E2F1 target. We showed that CTSL2 is not only required for E2F1-induced apoptosis by engaging LMP but its level also modulates the cellular sensitivity to HDACi. These data provide a role for CTSL2 as a novel pro-apoptotic target of E2F1, which might be potentially important in determining the therapeutic response of HDACi.
RESULTS
Exogenous E2F1-dependent transcriptional profiling identifies CTSL2 as a potential E2F1 target Induction of E2F1 could lead to transactivation of its downstream targets, many of which are potent inducers of apoptosis. To systematically identify E2F1 targets, we made use of a p53-deficient Saos-2 osteosarcoma cell line that expresses an exogenous E2F1 fused to the 4-hydroxytamoxifen (4-OHT)-responsive ligand-binding domain of the estrogen receptor (ER). In this system, addition of 4-OHT leads to translocation of ER-E2F1 to the nucleus, thereby allowing the induction of E2F1 target genes. 17 Using this E2F1-confined system, we performed Illumina gene expression analysis and profiled E2F1-dependent gene expression ( Figure 1a ). Using a twofold cutoff, we identified a cluster of genes that are differentially regulated in Saos-2 pBabe and ER-E2F1 cells. In addition to many previously known E2F1 targets, such as CCNE1, APAF1 and caspase-3, we noticed that CTSL2, a previously undescribed target, was robustly induced following the 4-OHT treatment over different time course (Figure 1a) . Of further notice, CTSL2 seemed to be the most highly induced gene by E2F1, as compared with the rest of the cathepsin family member. We, thus, chose to focus on CTSL2, as the role for CTSL2 in apoptosis regulation has not been previously studied. The array observation was further validated by quantitative reverse transcriptase-PCR analysis, which shows the induction of CTSL2 mRNA upon 4-OHT treatment in ER-E2F1-expressing Saos-2 cells, but not in Saos-2 cells expressing a DNA-bindingdeficient ER-E2F1 mutant (E132) (Figure 1b) . Moreover, induction of CTSL2 mRNA could not be inhibited by pre-treatment of the protein synthesis inhibitor, cyclohexamide, indicating that CTSL2 could be a direct target of E2F1 (Figure 1b) . Western blot analysis in Saos-2 ER-E2F1 cells treated with 4-OHT also confirmed the upregulation of CTSL2 protein concomitant with the known E2F1 target Cyclin E (Figure 1b, right panel) . A similar observation of CTSL2 mRNA and protein inductions by E2F1 were also found in U2OS ER-E2F1 cells (Figure 1c ).
CTSL2 is regulated by endogenous E2F1 and DNA damage response We next investigated whether CTSL2 expression is also regulated by endogenous E2F1. To this end, we began with the human lung fibroblast cells IMR90 and IMR90 cells transformed with oncoprotein E1A (IMR90/E1A). IMR90/E1A is known to activate the endogenous E2F1 by inhibiting the tumor suppressor pRB. 14 Indeed, we detected a much higher level of both E2F1 and CTSL2 mRNA and protein level in IMR90/E1A cells compared with nontransformed IMR90 cells (Figure 2a) . Moreover, E2F1 knockdown in IMR90/E1A cells resulted in a significant reduction in CTSL2 mRNA and protein expression, indicating a causal role for endogenous E2F1 in regulating CTSL2 (Figure 2b ).
Endogenous E2F1 can also be activated via protein stabilization by DNA damage. 18, 19 Consistently, we showed that the treatment of DNA-damaging agents, adriamycin and etoposide (also known as VP-16) in U2OS cells, resulted in marked induction of CTSL2 at both mRNA and protein levels accompanying E2F1 accumulation (Figure 2c ), which was abolished upon E2F1 knockdown (Figure 2d ). Taken together, these data provide substantial evidence that CTSL2 is regulated by E2F1 expressed both exogenously and endogenously.
To further validate the relationship between E2F1 and CTSL2 expression in a clinically relevant setting, we interrogated a gene expression data set that consists of a panel of 24 paired primary colorectal tumor and matched control samples. 20 We found that E2F1 and CTSL2 share a striking similarity in their expression pattern in these paired tumor and normal samples (Figure 2e) , with a Pearson correlation of 0.692 (Po0.001). This supports a direct correlation between E2F1 and CTSL2 expression level in patient samples. Taken together, the data support the endogenous regulation of CTSL2 by E2F1 and indicate that CTSL2 might be a clinically relevant E2F1 target in human cancer. CTSL2 is a direct binding target of E2F1 Next, we performed chromatin immunoprecipitation analysis to determine whether E2F1 can directly bind to the CTSL2 gene promoter in vivo. We used three different pairs of primers (P1 to P3) targeting different regions of CTSL2 promoter as shown in Figure 4a . Endogenous E2F1 pull down was performed with a specific E2F1 monoclonal antibody in U2OS cells treated with etoposide (1 mM) for 24 h, followed by genomic PCR analysis of the above three regions. Of notice, PCR analysis of the proximal promoter region encompassing the putative E2F1-binding site ( À 1180/ À 1173, P3) showed the highest enrichment of E2F1 following the drug treatment (Figure 4b ), while there is no significant enrichment in more distant regions (P1 and P2). This finding supports that E2F1 is recruited to the CTSL2 promoter following DNA damage and activates its transcription. In addition, E2F1 pull down in IMR90/E1A cells at promoter region Normal (n=24) Tumor (n=24) 13 33 (e) Raw expression values of E2F1 and CTSL2 mRNA levels in 24 paired colorectal normal and tumor samples extracted from our previously published microarray data (GEO accession number GSE10972). Correlation between E2F1 and CTSL2 mRNA level was measured as 0.692 by Pearson's product moment correlation with a P-value o0.001.
E2F1 target CTSL2 modulates drug-induced apoptosis C Hooi Wong et al ( À 1180/ À 1173, P3) also detected a significant enrichment of E2F1 compared with the IgG control ( Figure 4c ). Collectively, these data clearly established CTSL2 as a direct binding target of E2F1.
CTSL2 is required for E2F1-induced LMP and apoptosis We next assessed whether CTSL2 induction is involved in E2F1-induced apoptosis. In U2OS ER-E2F1 cells, exogenous E2F1 activation by 4-OHT treatment for 48 h resulted in marked cell death (47.14%), as assessed by fluorescence-activated cell sorting (FACS) analysis of cells in sub-G1, which was markedly reduced upon CTSL2 knockdown by two specific small interfering RNAs (siRNAs; 14.4% and 19.7%, respectively) ( Figure 5a ). Western blot analysis indicated reduced PARP cleavage upon 4-OHT treatment in both CTSL2 siRNA and short-hairpin RNA-mediated gene silencing, suggesting that CTSL2 is involved in a caspasedependent apoptotic cell death (Figure 5b) . To further ascertain a role of CTSL2 in E2F1-induced apoptosis, we performed FACSbased analysis on caspase-3 activity (Figure 5c ) and mitochondrial membrane potential by JC-1 staining (Figure 5d ). From the results of both assays, we conclude that CTSL2 knockdown markedly inhibited E2F1-induced apoptotic events. Collectively, these results indicate that E2F1-induced CTSL2 activation participates in apoptotic cell death. As CTSL2 is a lysosomal protease, we next investigated the possibility that E2F1 induces LMP through induction of CTSL2. To do this we made use of a lysomotropic probe, acridine orange (AO), which fluoresces red in acidic organelles such as lysosomes, while it remains in low concentration and fluoresces green in the nucleus. 21 Indeed, 4-OHT treatment of U2OS ER-E2F1 cells for 24 h resulted in a disappearance of red fluorescence of AO staining as well as a diffused red staining in the lysosomes, consistent with an LMP phenotype (Figure 5e ). This phenotype was effectively rescued by CTSL2 knockdown (Figure 5e ). We also observed enhancement of green fluorescence of the nucleus, which may indicate nuclei acidification, which was consistent with previous report 21 ( Figure 5e ). To add credence to this observation, we performed lysosomal membrane stability assay by using AO uptake method. 22 The reduction of red fluorescence of AO resulted in the increase of 'pale' cells, which indicates a reduced number of intact lysosomes. Again, addition of 4-OHT resulted in the increase of 'pale' cells in control cells, which was largely abrogated by CTSL2 knockdown (Figure 5f ). Taken together, these data suggested that induction of CTSL2 by E2F1 lead to LMP, mitochondrial membrane depolarization and caspase-3 activation, which eventually culminated in apoptotic cell death.
Next, we evaluated a role for CTSL2 in DNA damage-induced apoptosis, as we showed above that DNA-damaging agents can also activate E2F1-dependent CTSL2 expression (Figure 1c) . In U2OS cells, adriamycin or etoposide treatment for 48 h resulted in robust apoptosis, which was efficiently rescued upon CTSL2 knockdown, as examined by both FACS analysis and western blot analysis of PARP cleavage (Figures 5c and d) . Collectively, these Figure 3a . All the data in the bar graphs represents mean ± s.e.m., n ¼ 3. *Po0.05; **Po0.01.
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CTSL2 is critical for HDACi-induced apoptosis HDACi are novel classes of anticancer agents. 23 One of the proposed mechanisms for HDACi anti-tumor effect involves the apoptotic induction through various pathways, including E2F1-dependent apoptosis. 13, 16 We therefore sought to evaluate a possible role of CTSL2 in HDACi-induced apoptosis. We have shown above that CTSL2 expression exhibits various expression levels in colorectal cancer tumor samples (Figure 2e ). We also found that CTSL2 have a wide range of expression levels in a panel of colorectal cancer cell lines in which HCT116 and HT29 cells have markedly higher CTSL2 expression than SW620, RKO and normal colon (Figure 6a ). To determine a role of CTSL2 in HDACi response, we performed CTSL2 knockdown in HCT116 cells that shows highest expression of CTSL2. CTSL2 knockdown in both p53 wild-type and p53-deficient HCT116 cells markedly reduced the apoptosis response to two different HDACi, suberolynic acid (SAHA) and trichostatin A (TSA) (Figure 6b ). This indicates that expression of CTSL2 is required for HDACi-induced cell death and this effect is p53-independent. Conversely, enforced overexpression of CTSL2 in SW620 cells, which possessed the lowest expression of CTSL2, enhanced HDACi-induced apoptosis, as examined by both FACS and PARP cleavage analyses (Figure 6c ).
Of notice, CTSL2 overexpression alone did not induce apoptosis but promoted HDACi-induced apoptosis, which indicates that CTSL2 is not a sufficient apoptosis inducer but is required for priming the cancer cells to undergo apoptosis in stress conditions. Again, the ability of CTSL2 in promoting apoptosis does not require normal p53 as SW620 is a p53-mutant cell line. Moreover, in the non-colorectal cancer cell line U2OS, CTSL2 overexpression also sensitized suberolynic acid and trichostatin A-induced apoptosis (Figure 6d ). These findings lend credence to the CTSL2 knockdown data in HCT116 cells and further supported that CTSL2 expression level might be an important determinant of HDACiinduced apoptosis in human cancer cells.
DISCUSSION
Here, using multiple approaches we found and validated a novel and direct E2F1 target, CTSL2, that is implicated in cancer cell apoptotic induction. Importantly, we also demonstrated that CTSL2 could be an important molecular determinant of cell death response to cancer therapeutic treatments. This has advanced our understanding of E2F1-mediated cell death pathway in cancer treatment, as till date very few E2F1 targets have been functionally linked to therapeutic response.
CTSL2 was first cloned in 1998 and belongs to the human papain family of cysteine proteinases. 24 Because of its high sequence similarity with another member of the papain family, E2F1 target CTSL2 modulates drug-induced apoptosis C Hooi Wong et al cathepsin L, the novel gene is termed CTSL2 or cathepsin L2. Previously, cathepsin L2 was found to be highly expressed in the thymus, and was reported to be involved in positive selection of T-helper cells. 25 In addition, CTSL2 was found to be differentially expressed in colorectal and breast tumor tissue as compared with normal cells, 24 but its role in cancer has not been assigned till date. In this study, we provide compelling evidence that CTSL2 is a direct target of E2F1, and its induction is required for E2F1-induced apoptosis. CTSL2 was also upregulated upon chemotherapy-induced DNA damage, which activates endogenous E2F1. As such, knockdown of CTSL2 reduced the apoptotic response to chemotherapeutic drugs. This indicates that CTSL2 induction by E2F1 may be crucial for DNA-damaging chemotherapeutic agents to induce efficient cell death in cancer cells. Unlike other well-known E2F1 pro-apoptotic targets, such as caspases and Apaf1, that induce apoptosis through mitochondrial death pathway, the mechanism by which CTSL2 induces apoptosis remains to be determined. However, other papain family members such as cathepsin D and cathepsin B are well known to induce apoptosis by LMP. 26 Following LMP, cathepsins are also reported to translocate from the lysosomes to the mitochondria, and have been shown to proteolytically cleave downstream targets, such as Bid and caspases, leading to cell death execution. 27, 28 In agreement with our expectation, we demonstrated a role of CTSL2 in LMP activation associated with E2F1-induced apoptosis. It is possible that the proteolytic activity of CTSL2 contributes to the leakiness of lysosomal membranes, resulting in the release of lysosomal contents into the cytosol. As LMP was shown to be an early event in apoptosis, it could be probable that LMP mediated by CTSL2 could lead to mitochondrial membrane depolarization and eventual apoptosis. These results have provided a novel mechanistic insight into E2F1-induced apoptosis and uncovered a novel role for E2F1 in the induction of LMP through transcriptional activation of CTSL2.
E2F1-induced death pathways have been linked to HDACiinduced apoptosis. 13, 29 We have previously shown that Rb/E2F1 pathway is a target for HDACi-induced apoptosis, and that this pathway is dependent on the activation of Bim, a pro-apoptotic Bcl-2 family member that has a critical role in mitochondrialdependent apoptosis. 29 Moreover, we have also discovered that ASK1 is a novel direct target of E2F1 in response to HDACi treatment, which regulates E2F1 activity through a positive feedback mechanism. 13 We showed in this study that CTSL2 expression as an E2F1 pro-apoptotic target is required for efficient apoptosis induction by HDACi. In recent years, HDACi has emerged as a novel class of cancer therapeutic agents because of its tumor selectivity. Despite the success of HDACi in hematological malignancies, such as cutaneous T-cell lymphoma, 30 the use of HDACi for treatment of solid malignancies has been far from encouraging and resulted in various patients' response to the treatment. Hence, there is great clinical interest in developing biomarker strategies to stratify solid tumor patients for HDACi treatment. In line with this effort, we showed that CTSL2 expression could be an important determinant of HDACi sensitivity. Indeed, CTSL2 overexpression resulted in a dramatic increase in cancer cell death response to HDACi treatment, whereas its knockdown reduced the sensitivity to HDACi. Given a wide range of CTSL2 expression levels as we have shown in primary colorectal tumor samples, we postulate that CTSL2 could be a potential biomarker candidate for the prediction for HDACi response in colorectal tumors. Furthermore, CTSL2 is expressed in lower levels in normal colon tissues compared with the tumor samples, which may, at least in part, provide the tumor selectivity of HDACis. Collectively, these results uncovered a novel E2F1 pro-apototic target that may determine the sensitivity of cancer cells to DNA-damaging agents and HDACi, which may have translational value for cancer therapeutics.
MATERIALS AND METHODS

Cell culture and chemicals
The human colorectal carcinoma HCT116 cells and its derivative isogenic p53 À / À HCT116 cells were kindly provided by Dr Bert Vogelstein (John Hopkins University, MD, USA). IMR90-E1A cells were obtained from Dr C. Brancolini (University of Udine, Udine, Italy). Other cell lines used in this study, including human osteosarcoma U2OS and Saos-2, human lung fibroblast IMR90, colon cancers SW620 and RKO, were obtained from the American Type Culture Collection (Manassas, VA, USA). Saos-2 and U2OS cells stably expressing ER-E2F1 were generated as described previously. 16 All cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics in a 37 1C humidified incubator containing 5% CO 2 . 4-OHT, adriamycin and ETO were purchased from Sigma-Aldrich (St Louis, MO, USA). Trichostatin A was purchased from Cell Signaling Technology (Beverly, MA, USA) and suberolynic acid was from Alexis Biochemicals (San Diego, CA, USA). Lysotracker Green DND and AO dyes were purchased from Invitrogen (Carlsbad, CA, USA). Active Caspase-3 staining kit and JC-1 staining kit were from Becton Dickinson (San Jose, CA, USA).
Plasmids and stable cell lines pcDNA4-E2F1 was generated by real-time PCR using total RNA from normal colon tissue. Retroviral-mediated gene transfer was performed using pMN-GFP/IRES retrovirus vector-expressing CTSL2 tagged to hemagglutinin. Infected cells were sorted by green fluorescent protein signals and expanded for in vitro studies. All constructs were confirmed free of mutation by sequencing.
RNA interference
Specific siRNA oligos targeting E2F1 and CTSL2 mRNAs and non-targeting control siRNA were from 1st Base Technology (Singapore). Cells were sequentially transfected two times at 48-h interval to secure efficient gene silencing. Cells were transfected with 100 nM final concentration of siRNA duplexes using Lipofectamine RNAiMax (Invitrogen) following the manufacturer's instructions. SiCTSL2#1 targets the following sequence: 
Dual luciferase reporter assays
Genomic DNA containing the human CTSL2 promoter elements were cloned into pGL3-luciferase reporter construct (Promega, Madison, WI, USA). HCT116 and HEK293T cells were transfected with either pcDNA4 empty vector (50 ng) or pcDNA4-E2F1 (50 ng) along with 10 ng of pRL-Null Renilla Luciferase and pGL3 basic constructs as indicated in Figure 2a . Transient transfection was performed using Fugene HD transfection reagents (Promega). Transfected cells were collected 48 h upon transfection, and relative luciferase activity was measured by the Dual Luciferase System (Promega). Data are represented as fold change normalized with the respective Renilla luciferase reading.
Immunoblot analysis
Protein extracts were prepared by lysis in RIPA buffer (containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 50 mM NaF, 0.1 mM Na 3 VO 4 ) and protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Lysates were resolved by SDS-polyacrylamide gel electrophoresis, transferred onto an immobilon membrane (Millipore, Billerica, MA, USA) and probed with indicated antibodies. Antibodies used in this study include: anti-E2F1 (Santa Cruz, CA, USA), anti-CTSL2 (Abcam Inc, Cambridge, MA, USA), anti-cleaved PARP (Cell Signaling Technology), anti-HA mouse monoclonal (Santa Cruz) and anti-actin mouse monoclonal antibody (Sigma-Aldrich).
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Microarray gene expression analysis and quantitative real-time PCR assay Total RNA was isolated using Trizol (Invitrogen) and purified with the RNeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription was performed using an RNA Amplification kit (Ambion, Carlsbad, CA, USA). The microarray hybridization was performed using the Illumina Gene Expression Sentrix BeadChip HumanRef-8_V2 (Illumina, San Diego, CA, USA), and data analysis was performed using GeneSpring software from Agilent Technologies (Santa Clara, CA, USA) as described. 31 qRT-PCR was assessed using the PRISM 7900 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) with specific probes from 1st Base Technology. Samples were normalized to the levels of 18S mRNA. Primer sequences are available upon request.
Flow cytometry and cell-cycle analysis Cells were collected and fixed in 70% ethanol. Fixed cells were stained with propidium iodide (50 mg/ml) after treatment with RNase A (100 mg/ml). The stained cells were analyzed for DNA content by FACS in a FACS Calibur (Becton Dickinson Instrument). Cell-cycle fractions were quantified using the CellQuest software (Becton Dickinson).
Active caspase-3 staining Cells were treated with 4-OHT for 48 h. Cells were then collected and stained with anti-caspase-3 antibody conjugated to FITC according to manufacturer's instructions (Becton Dickinson), and fluorescence was measured using CellQuest software (Becton Dickinson).
JC-1 staining
Cells were treated with 4-OHT for 48 h. Cells were then collected and stained with JC-1 dye according to the manufacturer's instructions (Becton Dickinson), and fluorescence were measured using CellQuest software (Becton Dickinson).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed, as described previously. 29 Briefly, sonicated extracts were precleared and incubated with antibodies specific to either E2F1 (c-20, Santa Cruz) or IgG control (SC-2027, Santa Cruz) at 4 1C overnight on a 360-1C rotator. The immunoprecipitated DNA was quantitated by quantitative real-time PCR using Applied Biosystems 7900HT Fast Real-Time PCR System (Applied Biosystems). The enrichment of E2F1 binding at the examined regions was quantitated relative to the input DNA followed by normalization to the respective IgG control values. Primer sequences used are as follows: P1: AO staining AO is a lysomotropic probe that preferentially accumulates in the acidic compartments in its charged form (AOH þ ). 32 For AO staining and confocal microscopy, U2OS ER-E2F1 cells were counted and reseeded in a coverglass slide chamber (Becton Dickinson) following CTSL2 knockdown. Cells were treated with or without 4-OHT (300 nM) for 24 h before staining with AO (5 mg/ml) for 15 min. Cells were then analyzed via confocal microscopy at a excitation wavelength of 488 nm.
Lysosomal membrane stability assay by AO uptake U2OS ER-E2F1 cells were treated and stained as in AO staining as described above. The cells were analyzed by flow cytometry by determining the percentage of 'pale cells', or cells which have reduced number of intact lysosomes by measuring the decrease in red fluorescence following 4-OHT treatment.
Statistical analysis
Statistical analysis was conducted using two-tailed Student's t test. Correlation of E2F1 and CTSL2 mRNA expression level in Figure 2e was measured via Pearson's product moment correlation. A P-value of o0.05 was defined as statistically significant.
